Comparison of 2-year clinical outcomes between zotarolimus-, sirolimus-, and paclitaxel-eluting stents in real life clinical practice

Ji Hyun Kim, Kyung Woo Park, Woo Hyun Lim, Dong Ho Shin, Sang Hoon Na, Bon Kwon Koo, Tae Jin Youn, In Ho Chae, Dong Ju Choi, Hyo Soo Kim

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Background: There are few studies comparing the long-term efficacy and safety of the zotarolimus-eluting stent (ZES) with sirolimus- (SES) and paclitaxel-eluting stents (PES) in the unselected cohorts that were subject to real life clinical practice. Methods: Total 2,769 patient who underwent successful percutaneous coronary intervention (PCI) with the three drug-eluting stents (DES) between April 2006 and July 2008 were analyzed retrospectively. A total of 1,152 patients were treated with SES, 810 with PES, and 807 with ZES. The primary analysis endpoint was cumulative rate of target-lesion failure (TLF) at 24 months, defined as the composite of cardiac death, target-vessel-related myocardial infarction (MI), and target-lesion revascularization (TLR). Results: At 24 months, the incidence of TLF was significantly lower in the SES group compared with the ZES (7.6% vs. 11.3%, HR = 0.66, CI = 0.49-0.88, P = 0.005) or the PES group (7.6% vs. 10.2%, HR = 0.74, CI = 0.55-0.99, P = 0.048), while similar between the PES and the ZES groups (HR = 0.89, CI = 0.66-1.20, P = 0.443). The difference was mostly driven by higher rate of TLR in the ZES and PES groups compared with the SES group, mostly within the first year post-PCI. However, the rate of hard endpoints (cardiac death or nonfatal MI) was similar among the three groups. These results were reproduced in the propensity score-matched cohort.Conclusions: This observational study shows that the use of SES is superior to PES or ZES for the TLF in the overall and matched analysis. © 2011 Wiley Periodicals, Inc.

Original languageEnglish
Pages (from-to)349-359
Number of pages11
JournalCatheterization and Cardiovascular Interventions
Volume83
Issue number3
DOIs
StatePublished - 15 Feb 2014

Keywords

  • PES
  • SES
  • ZES
  • all comer
  • drug-eluting stent
  • target-lesion failure

Fingerprint

Dive into the research topics of 'Comparison of 2-year clinical outcomes between zotarolimus-, sirolimus-, and paclitaxel-eluting stents in real life clinical practice'. Together they form a unique fingerprint.

Cite this